TMEM106B deficiency exacerbates α-synuclein aggregation in Parkinson’s disease
Brain · 07.09.2026 · 149 (9) · 3150-3165
DOI: 10.1093/brain/awag065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 17.02.2026. Verfasst von Lanxia Meng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Renmin Hospital of Wuhan University, Wuhan 430060, China. Hauptthemen laut MEDLINE: alpha-Synuclein, Membrane Proteins, Parkinson Disease, Nerve Tissue Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Innovative Research Groups of Hubei Province.
Abstract (Originalsprache)
Parkinson’s disease is an age-related neurodegenerative disease that is characterized by the deposition of α-synuclein aggregates in the brain. Nevertheless, the molecular mechanisms that regulate α-synuclein aggregation have not yet been identified fully. TMEM106B is a lysosomal transmembrane protein that has been reported to be associated with brain ageing and neurodegenerative diseases, including Parkinson’s disease. Here we show that TMEM106B is reduced in the brains of patients with Parkinson’s disease. Knockout of Tmem106b increases the formation of α-synuclein aggregates in primary neurons and mouse brains. TMEM106B deficiency results in impaired lysosomal acidification, lipid metabolism disorders and lipid droplet deposition in neurons. Interestingly, lipid droplets promote α-synuclein aggregation, resulting in the formation of α-synuclein fibrils with enhanced seeding activity and neurotoxicity in comparison to α-synuclein fibrils formed in the absence of lipid droplets. TMEM106B deficiency also leads to retardation of α-synuclein degradation by reducing the enzymatic activity of the lysosomal protease cathepsin D. Taken together, these results indicate that TMEM106B deficiency contributes to Parkinson’s disease pathogenesis by accelerating α-synuclein aggregation and halting α-synuclein degradation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
- College of Life Sciences, Wuhan University, Wuhan 430072, China.
- TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan 430072, China.
ORCID-Profile: Wenxuan Zou, Zhentao Zhang
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Innovative Research Groups of Hubei Province
- Natural Science Foundation Innovation Development Joint Fund Projects
Zitieren
APA
Meng, L., Liu, C., Li, M., Gong, H., Gu, X., Zou, W., Liu, H., Teng, H., Xiong, J., & Zhang, Z. (2026). TMEM106B deficiency exacerbates α-synuclein aggregation in Parkinson’s disease. Brain, 149(9), 3150-3165. https://doi.org/10.1093/brain/awag065
Vancouver
Meng L, Liu C, Li M, Gong H, Gu X, Zou W, et al. TMEM106B deficiency exacerbates α-synuclein aggregation in Parkinson’s disease. Brain. 2026;149(9):3150-3165. doi:10.1093/brain/awag065
BibTeX
@article{Meng2026,
author = {Meng, Lanxia and Liu, Congcong and Li, Meihui and Gong, Huangchuan and Gu, Xiaoling and Zou, Wenxuan and Liu, Han and Teng, Hanying and Xiong, Jing and Zhang, Zhentao},
title = {TMEM106B deficiency exacerbates α-synuclein aggregation in Parkinson’s disease},
journal = {Brain},
year = {2026},
volume = {149},
number = {9},
pages = {3150--3165},
doi = {10.1093/brain/awag065}
}
EUVIMED